1. Home
  2. CDLR vs ANIP Comparison

CDLR vs ANIP Comparison

Compare CDLR & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cadeler AS

CDLR

Cadeler AS

HOLD

Current Price

$26.23

Market Cap

1.5B

Sector

N/A

ML Signal

HOLD

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$78.90

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDLR
ANIP
Founded
2008
2001
Country
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.8B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CDLR
ANIP
Price
$26.23
$78.90
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$107.33
AVG Volume (30 Days)
133.4K
404.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$144.16
$44.10
Revenue Next Year
$69.44
$13.18
P/E Ratio
$7.19
$47.11
Revenue Growth
N/A
N/A
52 Week Low
$15.37
$54.10
52 Week High
$26.35
$99.50

Technical Indicators

Market Signals
Indicator
CDLR
ANIP
Relative Strength Index (RSI) 72.96 46.40
Support Level $25.58 $75.30
Resistance Level $26.35 $83.80
Average True Range (ATR) 0.61 2.67
MACD 0.08 -0.35
Stochastic Oscillator 94.89 47.76

Price Performance

Historical Comparison
CDLR
ANIP

About CDLR Cadeler AS

Cadeler AS is an offshore wind farm vessel contractor. It is engaged in offshore wind farm construction, maintenance, and decommissioning and provides marine and engineering operations to the wind industry, focusing on safety and the environment. The company operates six offshore jack-up wind farm installation vessels. In addition to wind farm installation, these vessels can perform maintenance, construction, decommissioning, and other tasks within the offshore industry.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Share on Social Networks: